webinar recording available - register to watch

Clinical Trial Continuity in Asia-Pacific during the COVID-19 Pandemic

Sites across the Asia-Pacific region have quickly changed how they manage trials, and most are able to deliver the clinical trial services their clients need. Biotech companies are currently initiating more clinical trials in Asia and Australia/New Zealand than in North America. During this briefing we will also discuss how:

  • The status of COVID 19 in the region and the factors that have driven the relatively low spread
  • Regulatory guidance and acceptability of remote monitoring and de-centralized clinical trials in Asia-Pacific
  • Risk management strategies
watch the webinar

No cost to register, subject to confirmation

If you are experiencing problems with your registration, please try the Zoom registration page.

Alejandro D. Ricart

Alejandro D. Ricart

Vice President, Clinical Development at TG Therapeutics

Alejandro is part of the Oncology Senior Leadership Team and is responsible for both small molecule and biologic programs. Prior to this role, Alex was Executive Medical Director at Oncology Early Development Strategy & Innovation at Novartis Pharmaceuticals Corporation. Alex was also Senior Director Late Development at Merck & Co., Inc. He played a key role in Pembrolizumab (KEYTRUDA®) Breakthrough Therapy Designation and in the Supplemental Biologics License Application (sBLA) for Hodgkin lymphoma.

Hannah Tarrant

Hannah Tarrant

Project Director, Novotech

Hannah Tarrant has 18 years of clinical research experience including 10 years as a Project Manager across EU, US and APAC, and has been a Project Director at Novotech Australia for the last 4 years. In this role she provides senior level oversight for phase I to IV studies across the APAC region and multiple therapeutic areas. She has also led multiple initiatives across the company, most recently driving Novotech’s Project Management response to the COVID-19 pandemic.

Daniela Caiazza

Daniela Caiazza

Director Clinical Operations ANZ, Novotech

Daniela joined Novotech in 2009 and since starting her role as Director of Clinical Operations ANZ in 2018 is responsible for the strategic planning and management of the clinical operations team to ensure project deliverables. Previous to Novotech, Daniela worked with Pfizer Pharmaceuticals. Daniela comes from a strong academic research background in cardiovascular and heart disease-related drug development and holds a BSc (Hons) and PhD in Chemistry.

Yooni Kim

Yooni Kim

Executive Director, Asia Operations, Novotech

Dr. Kim is responsible for overseeing Novotech’s operations and project delivery within the Asia region. Prior to joining Novotech, Dr. Kim worked at PRA Health Sciences as Director of Operations for North Asia. Dr. Kim is very experienced in Asia’s drug development industry, having managed operations for South Korea, Taiwan, China, Hong Kong, Singapore, Malaysia, Indonesia, Thailand, the Philippines and Japan. She has also worked at various positions in clinical development, medical affairs, and pharmacovigilance at GSK.

Kristyn Munro
moderator

Kristyn Munro

Director, Business Development Operations, Novotech

Kristyn leads Novotech’s Business Development Operations teams, encompassing both Client Operations and Proposals, Budgets and Contracts. Kristyn has enjoyed a career in clinical development for over twenty years, having worked for Bristol-Myers- Squibb, Astra-Zeneca and Amgen, prior to joining Novotech in 2009.